Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Proteins, Antibodies, ADCs Logo (drop shadow)

PART OF NEXTGEN BIOMED 2026

24 - 25 March 2026 | QEII Centre, London, UK

+ WORKSHOP DAY ON 23 MARCH 2026

Programme Summary

Join world-class experts at our annual Proteins, Antibodies & ADCs programme – uncover breakthrough strategies, pioneering technologies, and transformative innovations shaping the next generation of biotherapeutics. From cutting-edge protein and antibody engineering to advanced bioanalytics, real-world case studies, and game-changing
upstream and downstream processing, this programme delivers the insights driving tomorrow’s therapies today.

Build Your Personalised Agenda

See what you can't miss.

A personalised event programme built around your company, goals and interests — in seconds. No login required.

Untitled-3
Exhibitly AI Report Previews

DAY TWO

Proteins, Antibodies, ADCs Keynote Address

CHARLOTTE DEANE MBE, Professor, University of Oxford

Professor Charlotte Deane MBE is a bioinformatician at the University of Oxford, known for pioneering work in protein and antibody modelling and for developing widely used research tools. She led UKRI’s COVID-19 response, earning an MBE in 2022, and has held senior roles including Head of Oxford’s Statistics Department. In 2023, she became Executive Chair of EPSRC, highlighting her impact on science, leadership, and policy.

2026 Highlights

Dive into breakthrough technologies shaping biologics discovery & development from protein and antibody display to AI-driven engineering, stability-focused analytics, multi-specifics, novel formats, and end-to-end insights in upstream & downstreamprocessing.

Follow the full journey of ADC innovation - smarter design, translational success,
and strategies to boost efficacy while minimising toxicity. Learn from case studies and
preclinical data powering safer, next-generation conjugates.

NextGen Biomed - What to Expect Presenting 2
NextGen Biomed - What to Expect Networking 4
1000

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments
NGB + LSX Combined Logo-1

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.

NGB Newsletter Icon-1

Proteins, Antibodies, ADCs Agenda at a Glance

WORKSHOP DAY - 23 MARCH

Track 1: Protein & Antibody Engineering  
Track 2: Protein & Antibody Design  
Track 3: Novel Computational Tools & Technologies

DAY ONE - 24 MARCH

Track 1: Antibody Discovery & Selection: Novel Tools & Technologies 
Track 2: ADC Design, Validation & Optimisation to Enhance Their Therapeutic Potential 
Track 3: Emerging Analytical Techniques, Developability & Quality Control Systems
Track 4: Bioprocessing: Upstream Development: Novel Strategies for Cell Line Development & Expression Optimisation  
Track 5: NextGen Multi-Specifics, Cell Engagers & Other New Modalities  

DAY TWO - 25 MARCH

Track 1: AI/ML-Guided Protein & Antibody Engineering
Track 2: ADC Pre-Clinical & Translational Development 
Track 3:  Analytical Development: Stability & In-Depth Characterisation Methods for Proteins & Antibodies 
Track 4: Downstream Development: Protein Purification & Recombinant Protein Production

NextGen Biomed Conference Brochure

Meet Our Expert Speakers

Proteins & Antibodies again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Chris Herring
VP Safety,
T-Therapeutics
Karen Silence
Vice President, Head of Preclinical Product Development ,
Argenx
Paul Kellam
Chief Scientific Officer,
RQ Biotechnology
Show More Speakers
Hide Speakers
Agnieszka Lewandowska
Associate Director Analytical Development,
Immunocore
Aidan Riley
Associate Scientist,
AstraZeneca
Amberley Stephens
Associate Principal Scientist,
AstraZeneca
Amjad Khan
Global Digital,
Pfizer
Andreas Hollenstein
Principal Scientist, Immunosafety,
Roche
Andreas Plueckthun
Professor Of Biochemistry, Director, Department Of Biochemistry,
University of Zurich
Angus Sinclair
Chief Scientific Officer,
LabGenius Therapeutics
Annabelle Herrington-Symes, PhD
Biologics Discovery & Development Senior Scientist,
LifeArc
Antima Gupta
Senior Application Scientist,
Collaborative Drug Discovery
Barbara Ciani
Senior Lecturer,
University of Sheffield
Beth Wensley
Principal Scientist - Protein and Analytical Sciences,
LifeArc
Birgit Piater
Associate Scientific Director, ADC Biology,
Merck Healthcare KGaA
Blake Mazzitelli
Senior Scientist II,
Maxion Therapeutics
Campbell Stewart
Principal,
Novo Holdings
Charlotte Deane
Professor,
University of Oxford
Christian Hunzinger
Head of CMC Development Proteins, ADCs & Chemical Entities - Global Technical Development,
BioNTech
Christopher Lloyd
Director,
AstraZeneca
Christopher Ullman
Chief Executive Officer,
Stratosvir Ltd
Colby Souders
Cso,
Twist
Dan Kristensen
Scientific Director,
Symphogen A/S
Darryl Hayward
Antibody Discovery Scientist,
GSK
Denise Steckel
Industry Clinical Collaborations Lead,
Genentech
Dennis Ungan
Principal Scientist,
Novartis
Dimitri Sideris
Senior Scientist,
AstraZeneca
Dorothy Bray
Senior Executive,
Celtic Biotech
Elaine Dymond
Managing Director,
Dymond Pharma Consultancy Limited
Esam Abualrous
Principal Scientist I,
Schrödinger
Fabio Centola
CQA Manager,
Merck & Cie KmG
Federico Riccardi Sirtori
Director, Head of NBE-DMPK Innovative Bioanalytics,
Merck & Cie KmG
Gokhan Yahioglu
Director of Medicinal Chemistry,
Antikor Biopharma
Gurdaman Singh
Scientific Investigator,
GSK
Hans Melo
CEO,
Menten AI, Inc
Joost Uitdehaag
Head of Biology,
Crossfire Oncology B.V.
Justyna Mysliwy
Bioconjugation Team Leader,
Glythera Ltd
Karin Hrovatin
Bioinformatic Scientist,
Merck KGaA
Kate Smith
Senior Director,
GlaxoSmithKline
Katy Lloyd
Associate Director,
Genmab
Kerstin Papenfuss
Director Pharma,
Deep Science Ventures
Kiren Baines-Mortimore
Founder in Residence,
Deep Science Ventures
Lei Shi
Senior Vice President,
Biointron
Mali Eskandarpour
Senior Research Fellow,
University College London
Marc Vendrell Escobar
Professor of Translational Chemistry,
University of Edinburgh
Marjolein Van Egmond
Professor in Oncology and Inflammation,
Amsterdam UMC Genome Diagnostics
Mark Austin
Associate Director In vitro Display,
AstraZeneca
Matthew Burke
Senior Scientist,
UCB
Mattia Cocco
Associate Director,
AstraZeneca
Melissa Schutten
Executive Director,
Gilead Sciences
Mohammad Arastoo
Research Fellow,
University of Aberdeen
Nathan Alves
Research Director,
Indiana University School of Medicine
Nehil Chaturvedi
Senior Technical Project Lead,
Leukocare AG
Nicola Burgess-Brown
Professor Protein Sciences,
UCL
Obinna C Ubah
Principal Scientist/Programme Lead,
Elasmogen Ltd
Paolo Marcatili
Head of Antibody Design,
Novo Nordisk
Pin-Kuang Lai
Assistant Professor,
Stevens Institute of Technology
Poorvaja Ganesan
Scientist III Upstream Process Development,
Alexion Pharmaceuticals, Inc.
Randall Brezski
Director of Antibody Business Intelligence and Engagement,
The Antibody Society
Richa Garg
Senior scientist II,
AbbVie
Russell LaMontange
CEO,
Boston Immune Technologies and Therapeutics, Inc.
Saif Shubber
Associate Director,
Bicycle Therapeutics
Sara Trabulo
Associate Director,
AstraZeneca
Sarah Harris
Professor of Biological and Materials Physics,
University of Sheffield
Sebastian Birkedal
Senior Scientist Downstream Process Development,
Byondis
Sebastian Wolfgang Draxler
Head Of Laboratory - Analytical Development and Quality Control,
Bayer
Senior Representative
,
SeromYx
Silvia Crescioli
Antibody Therapeutics Pipeline Expert,
Independent Consultant
Simon Brunner
Principal,
Flagship Pioneering
Sofie Voet
Scientist,
argenx
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sridhar Neelamraju
Associate Principal Informatician,
AstraZeneca
Steffen Goletz
Professor, Department of Biotechnology and Biomedicine,
Danish Technical University
Stephanie Linker
Senior Computational Biochemist,
Merck & Cie KmG
Stephen Lock
Senior Market Development Manager, Biopharma, EMEAI,
SCIEX
Steven Rust
Senior Director Protein Engineering,
Gilead Sciences
Takashi Ebihara
Chief Operating Officer,
GeneFrontier Corporation
Thomas Kofoed
Chief Executive Officer,
Alphalyse
Tiffany Rau
Owner,
Rau Consulting LLC and Bio Pharma Technical Consulting
Victor Goldmacher
Chief Scientific Officer,
Immuviatx
Wenhui Song
Professor,
University College London
Yashas Kannan
Vice President Drug Discovery,
PentaBind

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients